These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31096947)

  • 1. The impact of immunosuppression on postoperative graft function after graft-unrelated surgery: a retrospective controlled cohort study.
    Lederer AK; Haffa D; Felgendreff P; Makowiec F; Fichtner-Feigl S; Huber R; Kousoulas L
    BMC Nephrol; 2019 May; 20(1):170. PubMed ID: 31096947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience.
    Smoter P; Nyckowski P; Grat M; Patkowski W; Zieniewicz K; Wronka K; Hinderer B; Morawski M
    Transplant Proc; 2014 Oct; 46(8):2786-9. PubMed ID: 25380918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
    González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
    Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
    Boratyńska M; Banasik M; Patrzałek D; Klinger M
    Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; El-Baz M; Shokeir AA; Ghoneim MA
    Ann Transplant; 2008; 13(4):46-54. PubMed ID: 19034223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
    Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA
    Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
    Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
    Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple immunosuppression with tacrolimus in pediatric renal transplantation: single-center experience.
    Duzova A; Aki T; Bakkaloglu A; Besbas N; Topaloglu R; Ozen S; Ozaltin F; Bilginer Y; Demirkaya E; Bakkaloglu M
    Transplant Proc; 2008; 40(1):132-4. PubMed ID: 18261567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients.
    Michielsen LA; van Zuilen AD; Verhaar MC; Wisse BW; Kamburova EG; Joosten I; Allebes WA; van der Meer A; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Hilbrands LB
    Nephrol Dial Transplant; 2019 Aug; 34(8):1417-1422. PubMed ID: 30561730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
    Hohage H; Welling U; Heck M; Zeh M; Gerhardt U; Suwelack BM
    Int Immunopharmacol; 2005 Jan; 5(1):117-23. PubMed ID: 15589469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function as a predictor of long-term graft survival in renal transplant patients.
    First MR
    Nephrol Dial Transplant; 2003 May; 18 Suppl 1():i3-6. PubMed ID: 12738756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.